Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD).

Fava M, Freeman MP, Flynn M, Judge H, Hoeppner BB, Cusin C, Ionescu DF, Mathew SJ, Chang LC, Iosifescu DV, Murrough J, Debattista C, Schatzberg AF, Trivedi MH, Jha MK, Sanacora G, Wilkinson ST, Papakostas GI

Open source

DOI
10.1038/s41380-018-0256-5
Published
2020 Jul
Container
Molecular psychiatry
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1038/s41380-018-0256-5,
  title = {Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD).},
  author = {Fava M and Freeman MP and Flynn M and Judge H and Hoeppner BB and Cusin C and Ionescu DF and Mathew SJ and Chang LC and Iosifescu DV and Murrough J and Debattista C and Schatzberg AF and Trivedi MH and Jha MK and Sanacora G and Wilkinson ST and Papakostas GI},
  year = {2020},
  journal = {Molecular psychiatry},
  doi = {10.1038/s41380-018-0256-5},
  url = {https://doi.org/10.1038/s41380-018-0256-5}
}

RIS

TY  - JOUR
TI  - Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD).
AU  - Fava M
AU  - Freeman MP
AU  - Flynn M
AU  - Judge H
AU  - Hoeppner BB
AU  - Cusin C
AU  - Ionescu DF
AU  - Mathew SJ
AU  - Chang LC
AU  - Iosifescu DV
AU  - Murrough J
AU  - Debattista C
AU  - Schatzberg AF
AU  - Trivedi MH
AU  - Jha MK
AU  - Sanacora G
AU  - Wilkinson ST
AU  - Papakostas GI
PY  - 2020
JO  - Molecular psychiatry
DO  - 10.1038/s41380-018-0256-5
UR  - https://doi.org/10.1038/s41380-018-0256-5
ER  - 

APA

M, F., MP, F., M, F., H, J., BB, H., C, C., DF, I., SJ, M., LC, C., DV, I., J, M., C, D., AF, S., MH, T., MK, J., G, S., ST, W., & GI, P. (2020). Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD).. Molecular psychiatry. https://doi.org/10.1038/s41380-018-0256-5

Source records